Welcome to Plenary Session.

I'm your host, Dr. Vinay Prasad.

I'm a practicing hematologist, oncologist, and I'm associate professor of medicine.

I'm interested in issues at the intersection of medicine, oncology, and health policy, and that's what you're going to get on this podcast.

Welcome to Season 2.

This week on plenary session, you're in for a real treat.

I'm back in the studio with the discussion of politosimab vidotin and relapse refractory DLBCL.

Is this trial suitable for regulatory approval?

You won't want to miss this discussion.

We're back in the JCO, reading a paper by Lori Sen and colleagues.

This is a pivotal trial, a trial that led to drug approval.

Afterwards, we're joined with Question of the Week with Dr. Emerson Chen.

And finally, an interview with Dr. Ali Kaki. Dr. Kaki is the chief fellow of

hematology oncology at the University of Washington, Fred Hutch Cancer Center, and he is here

to discuss a new paper that he led that appeared in the JNCCN. You won't want to miss this. It's a discussion

of gene expression profile guided risk-adapted treatment strategies, and it has philosophical

implications for every such risk-adapted strategy in all types of medical practice.

You won't want to miss this discussion.

But first, a thanks.

I want to thank those of you who've gone online and support this podcast on patreon.com.

Patreon subscribers get access to the slides from lectures I give on plenary session.

I also want to thank the hundreds of you who've gone to the iTunes store and reviewed this

...